All In Biotech

Drug Trial Radar · NCT03857542

A Phase 3 Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With Presbyopia

A Phase 3, Multicenter, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of AGN-190584 in Participants With Presbyopia

Last checked: Nov 19, 2026Latest source record: Dec 29, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 427 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

427

Actual

Start

Mar 1, 2019

Primary completion

Sep 10, 2020

Study completion Sep 10, 2020

Sponsor

Lead sponsor
AllerganAbbVie (ABBV)
Sponsor type
Industry
First posted
Feb 28, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical study will evaluate pilocarpine hydrogen chloride (HCl) ophthalmic solution (AGN-190584) in an expanded participant population to establish efficacy, safety, and tolerability versus the vehicle-control when administered, over a 30-day study intervention period, once daily bilaterally in participants with presbyopia.

Conditions

  • Presbyopia

Interventions

  • Pilocarpine HCl Ophthalmic SolutionDrug

    Pilocarpine HCl ophthalmic solution 1.25%, one drop in each eye, once daily, for up to 30 days.

  • VehicleOther

    Vehicle, one drop in each eye, once daily, for up to 30 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Gaining 3 Lines or More in Mesopic, High-contrast, Binocular DCNVA, Without Losing More Than 5 Letters of Mesopic, High-Contrast, Binocular CDVA With the Same Refractive Correction at Day 30, Hour 3Time frame: Baseline (Day 1) to Day 30 (Hour 3)

Locations

35 sites in 1 country. Site status is shown where the registry gives one.

  • Eye Center South

    Dothan, Alabama

  • M&M Eye Institute

    Prescott, Arizona

  • Walman Eye Center

    Sun City, Arizona

  • Milton M. Hom, OD, FAAO

    Azusa, California

  • Global Research Management

    Glendale, California

  • Advanced Vision Care

    Los Angeles, California

  • North Valley Eye Medical Group, Inc.

    Mission Hills, California

  • Eye Research Foundation

    Newport Beach, California

  • Corneal Consultants of Colorado

    Littleton, Colorado

  • Benjamin Knox Lambright, MD

    Crystal River, Florida

  • South Florida Vision Center

    Fort Lauderdale, Florida

  • Bowden Eye Associates

    Jacksonville, Florida

  • Mid Florida Eye Center

    Mt. Dora, Florida

  • Newsom Eye & Laser Center

    Sebring, Florida

  • Clayton Eye Center

    Morrow, Georgia

  • The Midwest Center for Sight

    Des Plaines, Illinois

  • Jacksoneye

    Lake Villa, Illinois

  • Kannarr Eye Care

    Pittsburg, Kansas

  • Heart of America Eyecare

    Shawnee Mission, Kansas

  • Cincinnati Eye Institute

    Edgewood, Kentucky

  • Chu Laser Eye Institute

    Bloomington, Minnesota

  • Silverstein Eye Centers

    Kansas City, Missouri

  • Moyes Eye Center

    Kansas City, Missouri

  • Tekwani Vision Center

    St Louis, Missouri

  • Amel Youssef, OD

    Las Vegas, Nevada

  • Debry Medical Services PC

    Las Vegas, Nevada

  • Bucci Laser Vision

    Wilkes-Barre, Pennsylvania

  • Waring Vision Institute

    Mt. Pleasant, South Carolina

  • University Eye Surgeons

    Maryville, Tennessee

  • Total Eye Care, PA

    Memphis, Tennessee

  • Keystone Research ltd. at Texan Eye

    Austin, Texas

  • The Cataract and Glaucoma Center

    El Paso, Texas

  • Texas Eye & Laser Ctr

    Hurst, Texas

  • Benjamin Travis Dastrup, MD

    Ogden, Utah

  • Vision Consultants and Surgeons

    Falls Church, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.